OTC · Drug Manufacturers - Specialty & Generic

CanSino Biologics Inc. (CASBF) Stock

$2.60 +0.00% OTC: CASBF Healthcare

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China.

Valuation

MetricValue
Price$2.60
Market Cap$908.20M
P/E Ratio1720.81
P/B Ratio2.57
P/S Ratio8.35
EPS (TTM)$0.00
52-Week High$6.99
52-Week Low$2.60
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-0.02%
ROA-0.01%
ROCE-0.03%
Gross Margin75.00%
Operating Margin-0.16%
Net Margin-0.09%
Debt/Equity0.24
Current Ratio4.11

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.3B$1.0B$345.0M$825.0M$1.0B
Operating Profit$1.9B$-1.4B$-2.0B$-403.0M$-113.0M
Net Profit$1.9B$-909.0M$-1.5B$-379.0M$27.0M
EPS$7.74$-3.69$-6.01$-1.53$0.11
Op Margin45.1%-132.8%-589.6%-48.9%-11.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$11.9B$11.5B$9.3B$8.0B$7.2B
Total Liabilities$3.3B$4.2B$4.0B$3.0B$2.1B
Cash$5.5B$3.4B$2.0B$1.6B$1.2B
Borrowings$1.4B$2.7B$2.7B$2.0B$1.3B

Latest News

Asian Value Stock Insights For June 2026 Simply Wall St. · Jun 3, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$2.0B$-1.9B$-916.0M$-169.0M$32.0M
Investing Cash Flow$-3.7B$-2.3B$-1.1B$-454.0M$170.0M
Financing Cash Flow$584.0M$-220.0M$-90.0M$-17.0M$11.0M
Net Cash Flow$1.0B$-2.1B$-1.3B$-490.0M$-264.0M
Free Cash Flow$811.0M$-3.0B$-1.5B$-626.0M$-153.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-60.62
EV / EBITDA49.61
FCF Yield-1.46%
Quick Ratio3.66
Interest Coverage-0.05
Return 1Y-35.82%
Return 3Y-7.45%
Return 5Y-93.49%

Ownership

Insiders Held26.85%
Institutions Held16.17%
Institutions Float Held22.10%
Institutional HolderSharesReport Date
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund1,259,7022026-04-30
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard Emerging Markets Stock Index Fd1,242,0002026-04-30
iShares, Inc.-iShares Core MSCI Emerging Markets ETF1,146,2002026-05-31
New World Fund Inc828,6002026-06-30
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Index Fd.199,8592026-04-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
APNHYAspen Pharmacare Holdings Limited $8.59 -4.98% -33.17 $3.81B 1.40%
ARSUFFagron N.V. $26.53 +0.00% 19.10 $1.95B 1.73%
CHSYFChina Medical System Holdings Limited $1.57 +0.00% 17.84 $3.80B 2.55%
CURLFCuraleaf Holdings, Inc. $9.70 -2.07% -24.17 $2.56B 0.00%
DMPHFDermapharm Holding SE $53.00 +0.00% 16.91 $2.63B 1.91%

About CanSino Biologics Inc.

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

CanSino Biologics Inc. is headquartered in CN.

CanSino Biologics Inc. (CASBF) stock trades at $2.60 with a market capitalization of $908.20M. The stock is valued at a price-to-earnings (P/E) ratio of 1720.81, price-to-book of 2.57, price-to-sales of 8.35. Over the past 52 weeks the stock has ranged between $2.60 and $6.99, and currently trades 62.8% below its 52-week high.

On profitability, CanSino Biologics Inc. generates a return on equity (ROE) of -0.02%, return on capital employed of -0.03%, an operating margin of -0.16%, a net profit margin of -0.09%.

Official website: www.cansinotech.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides